Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
| Revenue (TTM) | $2.44B |
| Gross Profit (TTM) | $2.35B |
| EBITDA | $1.02B |
| Operating Margin | 39.50% |
| Return on Equity | 44.40% |
| Return on Assets | 24.00% |
| Revenue/Share (TTM) | $9.33 |
| Book Value | $7.41 |
| Price-to-Book | 6.89 |
| Price-to-Sales (TTM) | 5.32 |
| EV/Revenue | 4.937 |
| EV/EBITDA | 11.79 |
| Quarterly Earnings Growth (YoY) | 26.20% |
| Quarterly Revenue Growth (YoY) | 10.60% |
| Shares Outstanding | $247.78M |
| Float | $214.12M |
| % Insiders | 1.84% |
| % Institutions | 107.13% |
Volatility is currently expanding
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating.
LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law.
Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell
Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis continues to execute across the key pillars of our business, positioning the company to deliver on our strategic objectives for 2026 and beyond,” said Michael M. Morrissey, Ph.D., President and Chief Executive O.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company's website. To access the conference call, please dial (800) 715-9871 (domes.
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EXEL and any ticker you trade — then tracks every position and per-strategy win rate.
